{
  "main_header": {
    "sid": 515837,
    "name": "Vivanza Biosci.",
    "stock_name": "Vivanza Biosci.",
    "full_name": "Vivanza Biosciences Ltd",
    "name_url": "stocks-analysis/vivanza-biosci",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1.79",
    "chg": -0.07,
    "chgp": "-3.76%",
    "dir": -1,
    "prev_price": "1.86",
    "mcapval": "7.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530057,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 67,
    "indexname": "India SENSEX",
    "isin": "INE984E01035",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "2.02 k",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/vivanza-biosci-515837-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vivanza Biosciences Downgraded to Strong Sell Amid Technical and Fundamental Weakness",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-downgraded-to-strong-sell-amid-technical-and-fundamental-weakness-3998309",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_mojoScore_3998309.png",
        "date": "2026-05-19 08:30:38",
        "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 18 May 2026. This revision reflects deteriorating technical indicators, persistent operating losses, and weak long-term fundamentals despite recent positive quarterly financial results."
      },
      {
        "title": "Vivanza Biosciences Falls 5.00%: Valuation Shifts and Q4 Losses Shape the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-falls-500-valuation-shifts-and-q4-losses-shape-the-week-3983601",
        "imagepath": "",
        "date": "2026-05-09 17:05:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>May 4:</strong> Week opens at Rs.2.00</p>\n                    <p><strong>May 6:</strong> Valuation shifts signal changing price attractiveness</p>\n                    <p><strong>May 8:</strong> Q4 FY26 results reveal sharp loss reversal despite revenue surge</p>\n                    <p><strong>May 8:</strong> Stock closes week at Rs.1.90 (-5.00%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1.90</div><div class=\"stat-change neg..."
      },
      {
        "title": "Are Vivanza Biosciences Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-vivanza-biosciences-ltd-latest-results-good-or-bad-3982328",
        "imagepath": "",
        "date": "2026-05-08 19:18:11",
        "description": "Vivanza Biosciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges despite remarkable year-on-year revenue growth. The company reported net sales of ₹6.36 crores, reflecting an extraordinary increase of 1,225.00% compared to the same quarter last year. However, this figure represents a substantial sequential decline of 85.94% from ₹45.25 crores in Q3 FY26, raising concerns about revenue volatility and sustainability.\n\nThe net profit for the quarter was a loss of ₹0.45 crores, marking a 325.00% decline from the previous quarter and a 55.00% decline year-on-year. This loss indicates that the company is currently loss-making on a trailing twelve-month basis, which has led to questions regarding its ability to achieve sustainable profitability.\n\nThe operating profit before depreciation, interest, tax, and other income (PBDIT) turned negative at -₹0.24 crores, resulting in a..."
      },
      {
        "title": "Vivanza Biosciences Ltd: Valuation Shifts Signal Changing Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-signal-changing-price-attractiveness-3976696",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_valuationdot_3976696.png",
        "date": "2026-05-06 08:00:25",
        "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in price attractiveness despite ongoing operational challenges and a tough market backdrop."
      },
      {
        "title": "When is the next results date for Vivanza Biosciences Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-vivanza-biosciences-ltd-3976541",
        "imagepath": "",
        "date": "2026-05-05 23:16:40",
        "description": "The next results date for Vivanza Biosciences Ltd is scheduled for 07 May 2026...."
      },
      {
        "title": "Vivanza Biosciences Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-3969338",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VivanzaBioscien_valuationdot_3969338.png",
        "date": "2026-04-30 08:00:22",
        "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite ongoing challenges reflected in its negative returns and profitability metrics, the stock’s current price-to-earnings and price-to-book value ratios suggest a more compelling entry point compared to peers and historical averages."
      },
      {
        "title": "When is the next results date for Vivanza Biosciences Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-vivanza-biosciences-ltd-3969194",
        "imagepath": "",
        "date": "2026-04-29 23:16:25",
        "description": "The next results date for Vivanza Biosciences Ltd is scheduled for 04 May 2026...."
      },
      {
        "title": "Vivanza Biosciences Gains 14.84%: 2 Key Factors Driving the Weekly Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-gains-1484-2-key-factors-driving-the-weekly-surge-3943078",
        "imagepath": "",
        "date": "2026-04-11 17:04:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>6 Apr:</strong> Week opens at ₹1.82</p>\n                    <p><strong>7 Apr:</strong> Valuation shifts highlight renewed price attractiveness</p>\n                    <p><strong>8 Apr:</strong> MarketsMOJO upgrades rating from Strong Sell to Sell</p>\n                    <p><strong>10 Apr:</strong> Week closes at ₹2.09, +14.84% weekly gain</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1.82</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.2.09</div><div class=\"stat-change positive\">..."
      },
      {
        "title": "Vivanza Biosciences Declines 5.76%: 3 Key Factors Behind the Weekly Slide",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-declines-576-3-key-factors-behind-the-weekly-slide-3922069",
        "imagepath": "",
        "date": "2026-03-28 15:08:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>23 Mar:</strong> Stock hits 52-week low at Rs.1.82 amid market downturn</p>\n                    <p><strong>24 Mar:</strong> Valuation shifts to fair grade with Strong Sell mojo rating</p>\n                    <p><strong>27 Mar:</strong> New 52-week low recorded at Rs.1.81</p>\n                    <p><strong>Weekly Close:</strong> Rs.1.80, down 5.76% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1.91</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1.80</div><div class=\"..."
      }
    ],
    "total": 15,
    "sid": "515837",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/vivanza-biosciences-515837"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Intimation Of The Meeting Of The Board Of Directors Pursuant To Regulations 29 And 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "15-Jun-2026",
      "details": "Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2026 inter alia to consider and approve 1.To authorise Mr. Sarang Bharatbhai Pathak (DIN: 02663344) to sign the Financial Statements for the financial year ended 31st March 2026 on behalf of the Board 2.To take note of the consent received from M/s. Dharti Shah & Co. and appoint it as an Internal Auditor of the Company for the Financial Year 2026-2027. 3.To consider and approve the appointment of Mr. Hemant Amrish Parikh as a Non-Executive Non-Independent Director of the Company. 4. To consider and approve the transfer of certain unverified shares to the Unclaimed Suspense Account pending verification of the identity and entitlement of the rightful shareholders and to authorize the Registrar and Share Transfer Agent to process and release such shares from the Unclaimed Suspense Account upon receipt and verification of the prescribed KYC and other supporting documents subject to confirmation by the Company and applicable laws.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "09-May-2026",
      "details": "In terms of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Please find enclosed copy of newspaper advertisement published in English daily Newspaper (Indian Express) and one daily newspaper (Financial Express) in Gujarati language of the region where the registered office of the Company is situated for extract of Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended on March 31st 2026",
      "source": "BSE"
    },
    {
      "caption": "Results- Quarterly And Year To End Dated 31St March 2026",
      "datetime": "07-May-2026",
      "details": "Audited Standalone Financial Results for the Quarter and Year ended on 31st March 2026 Took note of resignation of Hemant A. Parikh as an MD and Chaitra Arora a CS Reconstitution of Committees of the Board",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "(18 Jun 2026)"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Vivanza Biosciences Ltd has announced <strong>1:10</strong> stock split, ex-date: 24 Mar 23",
          "dt": "2023-03-24",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Vivanza Biosciences Downgraded to Strong Sell Amid Technical and Fundamental Weakness

2026-05-19 08:30:38

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 18 May 2026. This revision reflects deteriorating technical indicators, persistent operating losses, and weak long-term fundamentals despite recent positive quarterly financial results.

Read More

Vivanza Biosciences Falls 5.00%: Valuation Shifts and Q4 Losses Shape the Week

2026-05-09 17:05:41

Key Events This Week May 4: Week opens at Rs.2.00 May 6: Valuation shifts signal changing price attractiveness May 8: Q4 FY26 results reveal sharp loss reversal despite revenue surge May 8: Stock closes week at Rs.1.90 (-5.00%) Week OpenRs.2.00 Week CloseRs.1.90<div class="stat-change neg...

Read More

Are Vivanza Biosciences Ltd latest results good or bad?

2026-05-08 19:18:11

Vivanza Biosciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges despite remarkable year-on-year revenue growth. The company reported net sales of ₹6.36 crores, reflecting an extraordinary increase of 1,225.00% compared to the same quarter last year. However, this figure represents a substantial sequential decline of 85.94% from ₹45.25 crores in Q3 FY26, raising concerns about revenue volatility and sustainability. The net profit for the quarter was a loss of ₹0.45 crores, marking a 325.00% decline from the previous quarter and a 55.00% decline year-on-year. This loss indicates that the company is currently loss-making on a trailing twelve-month basis, which has led to questions regarding its ability to achieve sustainable profitability. The operating profit before depreciation, interest, tax, and other income (PBDIT) turned negative at -₹0.24 crores, resulting in a...

Read More

Vivanza Biosciences Ltd: Valuation Shifts Signal Changing Price Attractiveness

2026-05-06 08:00:25

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in price attractiveness despite ongoing operational challenges and a tough market backdrop.

Read More

When is the next results date for Vivanza Biosciences Ltd?

2026-05-05 23:16:40

The next results date for Vivanza Biosciences Ltd is scheduled for 07 May 2026....

Read More

Vivanza Biosciences Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-04-30 08:00:22

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite ongoing challenges reflected in its negative returns and profitability metrics, the stock’s current price-to-earnings and price-to-book value ratios suggest a more compelling entry point compared to peers and historical averages.

Read More

When is the next results date for Vivanza Biosciences Ltd?

2026-04-29 23:16:25

The next results date for Vivanza Biosciences Ltd is scheduled for 04 May 2026....

Read More

Vivanza Biosciences Gains 14.84%: 2 Key Factors Driving the Weekly Surge

2026-04-11 17:04:52

Key Events This Week 6 Apr: Week opens at ₹1.82 7 Apr: Valuation shifts highlight renewed price attractiveness 8 Apr: MarketsMOJO upgrades rating from Strong Sell to Sell 10 Apr: Week closes at ₹2.09, +14.84% weekly gain Week OpenRs.1.82 Week CloseRs.2.09...

Read More

Vivanza Biosciences Declines 5.76%: 3 Key Factors Behind the Weekly Slide

2026-03-28 15:08:59

Key Events This Week 23 Mar: Stock hits 52-week low at Rs.1.82 amid market downturn 24 Mar: Valuation shifts to fair grade with Strong Sell mojo rating 27 Mar: New 52-week low recorded at Rs.1.81 Weekly Close: Rs.1.80, down 5.76% for the week Week OpenRs.1.91 Week CloseRs.1.80<div class="...

Read More

View All News